Trial Profile

Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVX ONCO 1 (Primary)
Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Squamous cell cancer
Focus Therapeutic Use

24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Primary endpoint (Overall Survival at 26 weeks (OS)) has been met, according to Results presented at the 48th European Society for Medical Oncology Congress.
24 Oct 2023 Enrollment was closed early as primary endpoint was met ahead of schedule. An unplanned interim review of the first 10 pts revealed 7 had met the 26 weeks OS endpoint, according to Results presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com